FFA
NBIX icon

Fi3 Financial Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Fi3 Financial Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$302K Buy
2,294
+691
+43% +$91.7K 0.09% 135
2025
Q4 		$227K Buy
+1,603
New +$232K 0.07% 167

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fi3 Financial Advisors's NBIX Position: Q1 2026 in Review

Fi3 Financial Advisors increased its Neurocrine Biosciences (NBIX) stake by 43% in Q1 2026, buying an estimated $91.7K and bringing the position to 2,294 shares worth $302K. The position accounts for 0.09% of the portfolio, ranked #135.

Fi3 Financial Advisors first reported a position in NBIX in Q4 2025 and has held it in 2 quarters since. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Fi3 Financial Advisors held 2,294 shares of Neurocrine Biosciences worth $302K as of Q1 2026.
  • Fi3 Financial Advisors bought 691 Neurocrine Biosciences shares in Q1 2026, an estimated $91.7K.
  • Neurocrine Biosciences made up 0.09% of Fi3 Financial Advisors's portfolio in Q1 2026, its #135 holding.
  • Fi3 Financial Advisors first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 2 quarters since.
  • 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Fi3 Financial Advisors's 13F filing for Q1 2026, filed 7 May 2026.